Schedule M (Revised): India's GMP Requirements Under the Drugs Rules, 1945

Schedule M is the schedule to India's Drugs Rules, 1945 setting out Good Manufacturing Practices and requirements of premises, plant and equipment for pharmaceutical products. The legal reference is Schedule M, substituted by rule 5 of G.S.R. 922(E)_Notification%20of%20Schedule%20M%20of.pdf). Its title cross-refers to rules 71, 74, 76 and 78.

The names identify different things: Schedule M is the schedule containing the requirements; G.S.R. 922(E) is the notification identifier for the instrument that substituted it. The notification is dated 28 December 2023, as identified in the footnote to G.S.R. 127(E).pdf). “Revised Schedule M” therefore identifies the substituted text, not a separate parent set of rules.

In a procedure or gap assessment, cite the parent rules, the schedule and the specific paragraph together so each control points to a defined obligation.

For broader terminology, see cGMP and GxP; use the Schedule M provision itself when identifying the Indian requirement.

Read the revised text as a legal framework containing connected quality disciplines, not as a list of interchangeable certifications. G.S.R. 922(E), paragraph 5_Notification%20of%20Schedule%20M%20of.pdf), substitutes Schedule M. Its title covers GMP and requirements for pharmaceutical premises, plant and equipment; Part I sets out the main GMP principles.

Structurally, Part I_Notification%20of%20Schedule%20M%20of.pdf) sets out Good Manufacturing Practices for pharmaceutical products as the main principles, and later Parts add product-specific requirements. Each specific Part opens with a note in the same form; Part II, for example, states that the “Main principles as given in Part I shall be complied with, mutatis mutandis” for sterile products, parenteral preparations and sterile ophthalmic preparations, and that “In addition to these requirements, the following specific requirements shall also be followed”. A sterile, biological or API site therefore reads Part I first and then the Part for its product type.

• Part II: sterile products, parenteral preparations and sterile ophthalmic preparations.
• Part III: products containing hazardous substances such as sex hormones, steroids or cytotoxic substances.
• Part IV: biological products; Part V: radiopharmaceutical products; Part VI: phytopharmaceuticals.
• Part VIII: oral solid dosage forms; Part IX: oral liquids; Part XI: metered-dose inhalers.
• Part XII: active pharmaceutical ingredients; Part XIII: requirements of plant and equipment.

The list above is a reading aid for the Parts discussed here, not a complete inventory; confirm the Part that matches each product in the current notified text.

The organising relationship is explicit in paragraph 1.1_Notification%20of%20Schedule%20M%20of.pdf): PQS incorporates both GMP and QRM. Read the GMP definition in paragraph 3.1_Notification%20of%20Schedule%20M%20of.pdf) alongside the risk-process definition in paragraph 2.1_Notification%20of%20Schedule%20M%20of.pdf), rather than treating either as a substitute for the system.

PQR sits within paragraph 2.3: paragraph 2.3.1_Notification%20of%20Schedule%20M%20of.pdf) gives its product-and-process improvement purpose. Keep that separate from paragraph 1.6_Notification%20of%20Schedule%20M%20of.pdf), which addresses management review of quality-system operation with senior-management involvement.

For related terminology, see cGMP, ICH Q10 and ICH Q9. Use those as companion explanations, not replacements for the Schedule M provisions.

Schedule M’s opening cross-reference_Notification%20of%20Schedule%20M%20of.pdf) identifies rules 71, 74, 76 and 78. For a particular manufacturing licence, check the current provisions of those rules rather than inferring licence categories or their full scope from that reference alone.

Use the following matrix as a practical screening method, not a legal classification. Assess each product and activity separately, including where different product types share a site.

For destination-market orientation, consult the separate references on US drug GMP under 21 CFR 211 and EU GMP Annex 21 importation. Do not equate an Indian GMP reference with foreign-market approval. Record who owns the assessment and which questions remain unresolved.

Later amendments are published on CDSCO’s Gazette notifications page; check it before relying on any timeline in this article.

This map is limited to the framework and provisions discussed here. Check the current Schedule M text and applicable amendments before making a present-day applicability decision.

The original commencement rule matters because the 2025 proviso amends it. Rule 6 of G.S.R. 922(E)_Notification%20of%20Schedule%20M%20of.pdf) set implementation by turnover: large manufacturers (turnover above 250 crores) within six months from the date of publication of the rules, and small and medium manufacturers (turnover of 250 crores or less) within twelve months. The 2025 extension below attaches only to the small and medium entry.

G.S.R. 127(E), rule 2.pdf) inserts a proviso into the rule 6 table of the Drugs (Amendment) Rules, 2023. It applies to the Small and Medium manufacturers entry, immediately after “Twelve months from the date of publication of these rules”. This is a targeted amendment, not a replacement timetable for every manufacturer category.

Who could seek the extension?

The inserted proviso allowed small and medium manufacturers with turnover less than two hundred and fifty crores to seek an extension. It required an application to the Central Licence Approving Authority in Form A, within three months from publication of the notification, accompanied by a plan of upgradation. For such manufacturers, it stated that implementation would be extended until 31 December 2025.

These conditions matter: turnover alone did not establish fulfilment of the application requirements. The three-month application period and the implementation endpoint describe a historical route; they should not be read as an application window that remains open.

What Form A asked manufacturers to plan

Form A, item 5(i)–(viii).pdf) lists the gap-analysis categories: plant, equipment, lab equipment, HVAC system, utilities, technical staff, documentation and others. These are categories for the upgradation gap analysis, not a product quality review input list.

The form contains two distinct statements about starting work:

• Item 6.pdf) asks for an item-wise compliance plan or strategy against the item 5 gap analysis, starting on or before 31 March 2025.
• The undertaking.pdf) proposes initiating upgradation within three months from the application date.

Keep those statements separate when reading the form; neither should be rewritten into an invented replacement date. As a practical planning measure—not an additional Form A requirement—equipment-related actions can be linked to the site's commissioning and decommissioning records, so the upgrade plan connects to identifiable work.

Worked case: the strict turnover threshold

Assume two small or medium manufacturers report turnover on the same applicable basis, measured in crores: one reports 249 crores and the other exactly 250 crores. The first satisfies the numerical comparison, 249 < 250. The second does not satisfy 250 < 250. This example tests only the proviso's “less than” condition; it does not establish fulfilment of the other application conditions or create another manufacturer category.

Under Part I, paragraph 1.1_Notification%20of%20Schedule%20M%20of.pdf), attaining the quality objective is senior management’s responsibility and requires staff participation and commitment across departments. The pharmaceutical quality system is therefore not solely a quality-department task. A practical accountability structure should connect management direction with the people performing and overseeing the work.

Paragraph 1.7_Notification%20of%20Schedule%20M%20of.pdf) requires the system to be defined and documented, with a quality manual or equivalent documentation describing the quality management system, including management responsibilities. For implementation, treat that description as a map of how the quality management system operates, rather than an isolated policy statement.

Paragraph 1.6_Notification%20of%20Schedule%20M%20of.pdf) requires periodic reviews of system operation involving senior management, to identify opportunities for continual improvement of products, processes and the system itself. Unless otherwise justified, these reviews must occur at least annually. Keep this management review focused on system operation; the product quality review cycle is addressed separately.

Day to day, trace one quality objective from the manual through a procedure to recent completed records and then to management review; the readiness review later in this article uses the same walkthrough.

Qualification and validation under paragraph 5

Paragraph 5.1_Notification%20of%20Schedule%20M%20of.pdf) requires each company to identify what qualification and validation work is required to prove that the critical aspects of their particular operation is controlled, and paragraph 5.2 places the key elements of the programme in a validation master plan. Paragraph 5.3 defines the evidence stages: design qualification (DQ) that premises, utilities, equipment and processes were designed in accordance with GMP; installation qualification (IQ); operational qualification (OQ); and process validation, also called performance qualification (PQ), showing that a specific process shall consistently produce a product meeting its predetermined specifications and quality attributes.

Paragraph 5.4 extends this to significant changes that may affect product quality directly or indirectly, and paragraph 5.5 states that qualification and validation “shall not be considered as one-off exercises”: an on-going programme based on periodic review follows first implementation. Paragraphs 5.8 and 5.9 require predefined, approved protocols and a written report of results and conclusions, and paragraph 5.11 directs particular attention to analytical test methods, automated systems and cleaning procedures. See validation master plan for how such a plan is usually organised.

Complaints feed the same system

Paragraph 6.1_Notification%20of%20Schedule%20M%20of.pdf) requires all complaints and other information concerning potentially defective products to be carefully reviewed according to written procedures, with corrective action taken. Paragraph 6.2 requires a designated person responsible for handling complaints and deciding the measures to be taken, with sufficient supporting staff, and where that person is different from the authorised person, the authorised person is to be made aware of any complaint, investigation or recall. In practice, link each complaint to the batch, the investigation and any CAPA so the product quality review can see recurring signals rather than isolated tickets.

Under revised Schedule M, paragraph 2.2(a)_Notification%20of%20Schedule%20M%20of.pdf) requires evaluation of quality risk to rest on scientific knowledge and experience with the process, ultimately linking it to patient protection. The practical question is not simply whether an event occurred, but how it could affect product quality and the patient.

Paragraph 2.2(b)_Notification%20of%20Schedule%20M%20of.pdf) makes the effort, formality and documentation of QRM proportionate to the risk. Paragraph 2.1_Notification%20of%20Schedule%20M%20of.pdf) permits both proactive and retrospective application: QRM can look ahead or assess what has already happened.

Worked case 2: define the exposure boundary

Assume four batches of 20,000 tablets each were manufactured, and two passed through the same suspect equipment-use window. Total production is 4 × 20,000 = 80,000 tablets. The initial traceability boundary is 2 × 20,000 = 40,000 tablets.

Those 40,000 tablets are potentially affected inventory—not a measured number of defective tablets or an automatic rejection decision. As an illustrative assessment method, connect the deviation to each relevant batch record, then examine whether equipment history and process evidence support that boundary. Uncertainty about the window is a reason to reassess its limits, not to assume that the other batches are unaffected. Authorised people decide disposition after assessment.

Recommended assessment record

As a documentation practice, record the concern, exposure boundary, evidence, uncertainty, selected controls, responsible person and review trigger. These are suggested fields, not statutory field names. Explain how the evidence supports the controls and what new information would reopen the decision. That rationale is more useful than an unexplained red, amber or green label: it lets another reviewer understand the decision’s basis and limitations. A numerical score may organise an assessment, but should not replace the reasoning.

Under Part I, paragraph 2.3.1_Notification%20of%20Schedule%20M%20of.pdf), regular, periodic or rolling quality reviews cover all pharmaceutical products, including export-only products. For related terminology, see APR / PQR.

Review cycle and required inputs

Paragraph 2.3.2_Notification%20of%20Schedule%20M%20of.pdf) states that reviews shall normally be conducted and documented annually, taking previous reviews into account. Consult that paragraph for the complete required input list. Specifically, paragraph 2.3.2(l)_Notification%20of%20Schedule%20M%20of.pdf) requires review of technical agreements to ensure they are up to date; this is one input, not the whole review checklist.

Decisions, responsibilities and follow-up

Paragraph 2.3.3_Notification%20of%20Schedule%20M%20of.pdf) requires the manufacturer to evaluate review results and assess whether corrective and preventive actions or revalidation should be undertaken. CAPA must be completed in a timely and effective manner under documented procedures. Procedures must also govern ongoing action management and review, with their effectiveness verified during self-inspection. Completing the review therefore does not, by itself, complete its follow-up obligations.

The same paragraph permits grouping by product type—such as solid dosage forms, liquid dosage forms or sterile products—where scientifically justified. A technical agreement between the parties must define their respective responsibilities for producing the review. The authorised person responsible for final batch certification must ensure that the quality review is timely and accurate.

Worked case 3: interpreting a recurring event

Assume one product has 24 batches in the review period. Three batches have one defined recurring event, counted once per batch. The batch-level event frequency is 3 ÷ 24 × 100 = 12.5%. This is a review signal, not a legal rejection limit or proof that an action was effective. Keep the event definition and denominator visible so later comparisons measure the same thing.

Recommended operational sequence—not a prescribed statutory workflow:

1. Define the product scope, review period and any grouping rationale.
2. Connect evidence to the relevant batch records, then assess the event's risk significance.
3. Evaluate the evidence in the product review and record conclusions and proposed actions.
4. Assign action owners and obtain the appropriate human authorisation for decisions.
5. Evaluate follow-up evidence through a CAPA effectiveness check, rather than treating an action's completion date as proof of success.

Premises and packaging

The Note to Schedule M_Notification%20of%20Schedule%20M%20of.pdf) sets a manufacturing-premises boundary: the premises must be used exclusively for producing drugs, with no other manufacturing activity undertaken there. This is a restriction on premises use, not simply a requirement to separate different activities in the records.

Under paragraph 14.26_Notification%20of%20Schedule%20M%20of.pdf), containers and closures intended for use must meet pharmacopoeial requirements; second-hand or used containers and closures are prohibited. For bottles, paragraph 14.26.1_Notification%20of%20Schedule%20M%20of.pdf) requires a written cleaning schedule to be established and followed. A practical evidence connection is to associate packaging specifications and cleaning records with the relevant packaging lot and batches in which it is used.

Receipt, quarantine and rejection

Purchased intermediate and bulk products must be handled on receipt as starting materials under paragraph 14.28_Notification%20of%20Schedule%20M%20of.pdf). Finished products follow a distinct status transition: paragraph 14.29_Notification%20of%20Schedule%20M%20of.pdf) requires quarantine until final release, followed by storage as usable stock under conditions established by the manufacturer.

Rejected materials and products must be clearly marked and stored separately in restricted areas under paragraph 14.31_Notification%20of%20Schedule%20M%20of.pdf). Whatever action is taken must be approved by authorised personnel and recorded. Identification, restricted segregation and the authorised action record therefore address different parts of the control; none substitutes for the others.

Connect physical controls to evidence

As a practical control-design approach, link receipt records and location/status records to the affected material or batch. Use production context tagging to keep those connections intelligible, and distinguish a recorded released inventory bucket from the physical stock it represents. For example, stock marked rejected but recorded as available presents a physical-versus-recorded status mismatch. Treat that scenario as a design test: identify who reconciles the discrepancy, what evidence supports the correction and how unintended selection is prevented while it remains unresolved. These are recommended evidence connections, not a prescribed database design or an assertion about inspection findings.

For a Schedule M readiness programme, a linked evidence model is easier to review than disconnected folders. The diagram below shows one such model; its entity names are implementation choices, not statutory record types.

Preserve the evidence version used for each decision; linking only to the latest document can obscure the basis of an earlier review. Link improvement actions back to their originating findings and forward to closure evidence and authorisations.

Recover without silently changing decisions

1. Identify the incomplete or conflicting transfer and retain its source reference.
2. Isolate the affected transaction from downstream use and record the exception.
3. Reconcile the discrepancy against the source, recording the correction and its basis.
4. Repeat the acceptance checks and resume from a known accepted point, checking that replay creates no duplicates.

Correcting a transfer is not approval of the underlying quality decision. In this operating model, electronic routing, calculations and record linkage support work; authorised people make approval and batch release decisions. A completed import or green dashboard state is neither a substitute for that authority nor compliance certification.

Use this recommended implementation sequence to test whether responsibilities and evidence connect. It is not an additional statutory checklist or a prediction of inspection outcomes. For historical extension questions, refer back to the Form A conditions discussed above.

1. Establish the product and licence scope for the review, including relevant site activities.
2. Map each applicable provision to that scope; record the reasoning for exclusions.
3. Assign a named owner for each mapped control and identify who decides unresolved questions.
4. Identify effective procedures and the operational records showing their use, not merely document titles.
5. Record gaps, contradictions and missing evidence against the relevant provision.
6. Define actions, accountable owners, target dates and the evidence needed to demonstrate completion.
7. Route decisions to authorised people, retaining the decision and its rationale.
8. Review the result through the chosen management review process, keeping unresolved actions visible.

The following weaknesses are illustrative control-design examples, not a ranked list of CDSCO inspection findings.

Suggested reassessment triggers include changes to product scope, process, site arrangements, system interfaces or applicable regulatory text. Use change control to prompt reconsideration of affected mappings and evidence. These practical triggers are separate from the review frequencies expressly stated in the provisions discussed above.